ArticleMedicine2022
Overexpression of fatty acid desaturase 3 predicts poor prognosis in head and neck squamous cell carcinoma.
Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Article
- Exosomal transcript cargo and functional correlation with HNSCC patients' survival.BMC cancer · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide, because its discovery time is in the late stage of the disease, so it is important to develop HNSCC biomarkers to achieve the purpose of early detection and treatment. Fatty acid desaturase 3 (FADS3), the third member of the FADS family, is involved in sphingolipid biosynthesis. Here, we for the first time investigated FADS3 expression in HNSCC, as well as its potential biological function, prognostic value and its impact on the immune system. In this study, we used bioinformatics for gene expression analysis, clinicopathological analysis, enrichment analysis, and immune infiltration analysis of The Cancer Genome Atlas (TCGA) datasets. Statistical analysis was done using R. Tumor IMmune Estimation Resource (TIMER) and CIBERSORT were used to analyze the effect of FADS3 on immune responses in HNSCC. Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier (KM) survival analysis, and the Human Protein Atlas (HPA) data were used to validate the results from bioinformatics analysis. Our findings indicate that FADS3 influences HNSCC prognosis. High expression of FADS3 is related to higher lymphatic metastasis, histologic grade, and lymphovascular invasion. Gene set enrichment analysis (GSEA) revealed that FADS3 is related to inhibition of amino acid metabolism. CIBERSORT analysis showed high FADS3 expression correlates with reduced levels of B cells. FADS3 is a marker of HNSCC, and high expression of FADS3 is associated with poor prognosis of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.